These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 20385333)

  • 21. Pathogenesis of ophthalmopathy in autoimmune thyroid disease.
    Heufelder AE
    Rev Endocr Metab Disord; 2000 Jan; 1(1-2):87-95. PubMed ID: 11704996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoints: new insights into the pathogenesis of thyroid eye disease.
    Shu X; Shao Y; Chen Y; Zeng C; Huang X; Wei R
    Front Immunol; 2024; 15():1392956. PubMed ID: 38817600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation.
    Smith TJ
    Autoimmunity; 2003; 36(6-7):409-15. PubMed ID: 14669949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17.
    Hoa N; Tsui S; Afifiyan NF; Sinha Hikim A; Li B; Douglas RS; Smith TJ
    PLoS One; 2012; 7(4):e34173. PubMed ID: 22506015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis.
    Krieger CC; Place RF; Bevilacqua C; Marcus-Samuels B; Abel BS; Skarulis MC; Kahaly GJ; Neumann S; Gershengorn MC
    J Clin Endocrinol Metab; 2016 Jun; 101(6):2340-7. PubMed ID: 27043163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor.
    Smith TJ; Hoa N
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5076-80. PubMed ID: 15472208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
    Smith TJ; Janssen JAMJL
    Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogenesis of thyroid eye disease--does autoimmunity against the TSH receptor explain all cases?
    Wall JR; Lahooti H
    Endokrynol Pol; 2010; 61(2):222-7. PubMed ID: 20464711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune mechanisms in thyroid eye disease.
    Lehmann GM; Feldon SE; Smith TJ; Phipps RP
    Thyroid; 2008 Sep; 18(9):959-65. PubMed ID: 18752427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
    Khoo TK; Bahn RS
    Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.
    Wang Y; Smith TJ
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1735-48. PubMed ID: 24651704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Insights into the Pathogenesis of Graves' Ophthalmopathy.
    Bahn RS
    Horm Metab Res; 2015 Sep; 47(10):773-8. PubMed ID: 26361262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease?
    Bahn RS
    Endocrinol Metab Clin North Am; 2000 Jun; 29(2):287-96, vi. PubMed ID: 10874530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves' disease and Graves' orbitopathy.
    Marinò M; Rotondo Dottore G; Ionni I; Lanzolla G; Sabini E; Ricci D; Sframeli A; Mazzi B; Menconi F; Latrofa F; Vitti P; Marcocci C; Chiovato L
    J Endocrinol Invest; 2019 Apr; 42(4):471-480. PubMed ID: 30132285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pathophysiology of thyroid eye disease.
    Shan SJ; Douglas RS
    J Neuroophthalmol; 2014 Jun; 34(2):177-85. PubMed ID: 24821101
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-dependent cell-mediated cytotoxicity against orbital target cells in thyroid-associated ophthalmopathy and related disorders; close relationship between serum cytotoxic antibodies and parameters of eye muscle dysfunction.
    Barsouk A; Peele KA; Kiljanski J; Stolarski C; Nebes V; Kennerdell JS; Volpe R; Wall JR
    J Endocrinol Invest; 1996 Jun; 19(6):334-41. PubMed ID: 8844451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology of Graves' ophthalmopathy.
    Stiebel-Kalish H; Robenshtok E; Gaton DD
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():178-81. PubMed ID: 20467359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid-associated eye disease.
    Heufelder AE; Joba W
    Strabismus; 2000 Jun; 8(2):101-11. PubMed ID: 10980691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential Roles of CD34+ Fibrocytes Masquerading as Orbital Fibroblasts in Thyroid-Associated Ophthalmopathy.
    Smith TJ
    J Clin Endocrinol Metab; 2019 Feb; 104(2):581-594. PubMed ID: 30445529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.